Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
11.77
+0.25 (2.17%)
Nov 24, 2025, 4:00 PM EST - Market closed
Arvinas Revenue
Arvinas had revenue of $41.90M in the quarter ending September 30, 2025, a decrease of -59.08%. This brings the company's revenue in the last twelve months to $312.30M, up 93.85% year-over-year. In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth.
Revenue (ttm)
$312.30M
Revenue Growth
+93.85%
P/S Ratio
2.74
Revenue / Employee
$726,279
Employees
430
Market Cap
755.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARVN News
- 23 hours ago - Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire
- 19 days ago - Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 21 days ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 4 weeks ago - Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 4 weeks ago - Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire